CANbridge Life Sciences Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2012-06-12
- Employees
- 101
- Market Cap
- -
Phase 2 Study of CAN008 in Subjects With GBM
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT05447195
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03746288
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
- Conditions
- Glioblastoma
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT03152708
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02853565
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath